Immunogenicity cohort study in children with clinical pneumonia

Phase 4, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease and pneumonia, sponsored by Pfizer. Primary endpoints: Serotype-specific IgG geometric mean concentration at time of clinical pneumonia diagnosis and Serotype-specific MOPA geometric mean titers at time of clinical pneumonia diagnosis.